• Publications
  • Influence
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
The preclinical study supports clinical evaluation of MLN9708, alone or in combination, as a potential MM therapy, and combining MLN2238 with lenalidomide, histone deacetylase inhibitor suberoylanilide hydroxamic acid, or dexamethasone triggers synergistic anti-MM activity.
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Preclinical data showing efficacy of b-AP15 in MM disease models validates targeting DUBs in the ubiquitin proteasomal cascade to overcome proteasome inhibitor resistance and provides the framework for clinical evaluation of USP14/UCHL5 inhibitors to improve patient outcome in MM.
Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes
Targeting CD22 depletes and reprograms B-cells and reverses autoimmune diabetes, thereby providing a blueprint for development of novel therapies to cure autoimmune diabetes.
Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease
It is conceivable that this next-generation proteasome inhibitor may achieve bone beneficial effects in addition to its antimyeloma activity in patients with myeloma, given favorable data on pharmacologic properties and emerging clinical safety profile.
Comprehensive Dissection of PDGF-PDGFR Signaling Pathways in PDGFR Genetically Defined Cells
These four PDGFR genetically defined cells provided a platform to study the relative contributions of the pathways triggered by the two PDGF receptors and no genes were differentially expressed in the double null cells, suggesting minimal receptor-independent signaling.
The cytotoxicity of naturally occurring styryl lactones.
Cytotoxicity of two triterpenoids from Nigella glandulifera.
Morphological observations and cell cycle analysis suggest that these compounds inhibit the proliferation of hepatoma by inducing apoptosis and consequently kalopanaxsaponins A and I may be potential therapeutic agents for the treatment of parental and drug resistant hepatoma.
Antitumor activity and mechanisms of action of total glycosides from aerial part of Cimicifuga dahurica targeted against hepatoma
TGA may potentially find use as a new therapy for the treatment of hepatoma and may eventually be useful in the prevention or treatment of Hepatoma.